|
Outcome of stimulation in patients with clomiphene citrate-resistant polycystic ovary syndrome and comparison between HP-uFSH and r-FSH (* values are expressed as mean ± SD; ns = not significant) |
||||
| Overall |
HP-uFSH |
rFSH |
P |
|
|
|
||||
| N. of patients |
76 |
39 |
37 |
|
| N. of stimulation cycles |
76 |
39 |
37 |
|
| Total FSH dose (IU) * |
648 ± 498 |
833 ± 307 |
546 ± 346 |
0.002 |
| Duration of follicular phase (days) * |
12.1 ± 3.9 |
11.9 ± 3.6 |
12.2 ± 3.7 |
ns |
| No. of preovulatory follicles ≥ 18 mm at hCG * |
2.0 ± 0.9 |
2.0 ± 0.8 |
2.0 ± 0.9 |
ns |
| No. of follicles 12–17 mm at hCG * |
4.2 ± 2.1 |
4.2 ± 2.0 |
4.1 ± 1.9 |
ns |
| Size of the dominant follicle at hCG (mm) * |
20.8 ± 1.8 |
20.8 ± 1.6 |
20.9 ± 1. 7 |
ns |
| Endometrial thickness at hCG (mm) * |
10.7 ± 2.0 |
10.9 ± 1.7 |
10.5 ± 1.9 |
ns |
| Monofollicular cycles (%) |
28 (36.8) |
13 (33.3) |
15 (40.5) |
ns |
| Bi/trifollicular cycles (%) |
12 (15.8) |
6 (15.4) |
6 (16.2) |
ns |
| Cancelled cycles (%) |
36 (47.4) |
20 (51.3) |
16 (43.2) |
ns |
| Deliveries |
11 |
4 |
7 |
|
| Delivery rate/started cycle (%) |
14.5 |
10.3 |
18.9 |
ns |
| Delivery rate/ovulatory cycle (%) |
27.5 |
21.1 |
33.3 |
ns |
Revelli et al. Reproductive Biology and Endocrinology 2006 4:38 doi:10.1186/1477-7827-4-38 |
||||